TB CAB

Research, regulatory, and access considerations regarding pretomanid

TB CAB releases document outlining key considerations regarding pretomanid in anticipation of FDA public advisory committee meeting on the TB Alliance's new drug application for pretomanid.

Read More →

Advocates raise serious concerns about errors in the WHO guidelines for the treatment of drug-resistant TB

Advocates call on WHO leadership to act immediately and correct specific technical errors in the WHO guidelines for the treatment of drug-resistant TB.

Read More →

TB CAB statement on M72/AS01E TB vaccine candidate development

Statement by the Global TB Community Advisory Board to the High-level consultation on accelerating the development of the M72/AS01E tuberculosis vaccine candidate

Read More →

TB CAB statement on safety of using bedaquiline and delamanid together

Global TB CAB welcomes confirmation of safety of using bedaquiline and delamanid together, urges uptake.

Read More →

Advocates call on Otsuka to reduce the price of delamanid

Advocates ask Otsuka to lower the price of delamanid in line with Médecins sans Frontières target regimen cost of $500.

Read More →

Webinar on implementing an injectable-free regimen for drug-resistant TB - materials now available online

Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB), the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) and TB Proof hosted a webinar on 16 August 2018 on implementing an injectable-free regimen for drug-resistant TB.

Read More →

The TB CAB and TAG welcome WHO recommendation of injectable-free regimens for the treatment of RR/MDR-TB

The WHO, Ministries of Health and Finance, donors, implementers, technical assistance providers, civil society, and communities must work together to ensure rapid implementation.

Read More →

Webinar: Implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB

Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB) and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) will host a webinar on 16 August 2018 at 10 am EDT / 4 pm South Africa / 5 pm Kenya on implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB (DR-TB) in light of the new World Health Organization (WHO) policy brief on DR-TB regimens.

Read More →

Global TB CAB responds to new bedaquiline price

The TB CAB reiterates its request for Johnson & Johnson to commit to a global price for bedaquiline that is no higher than US$32 per month.

Read More →

Webinar: Implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB

Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB) and DR-TB STAT will host a webinar on 1 August 2018 at 10 am New York / 4pm South Africa / 5pm Kenya on implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB.

Read More →

Page 1 of 6 · Total posts: 10

1 2 Last→